Rebeccamycin

立即咨询

Rebeccamycin

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

93908-02-2

Rebeccamycin，一种抗肿瘤抗生素，抑制 DNA 拓扑异构酶 I (DNA topoisomerase I)。Rebeccamycin 通过毒害拓扑异构酶 I 发挥其主要的抗肿瘤作用，对蛋白激酶 C 和拓扑异构酶 Ⅱ 的作用较小。

生物活性

Rebeccamycin, an antitumorantibiotic, inhibitsDNAtopoisomeraseI. Rebeccamycin appears to exert its primary antineoplastic effect by poisoningtopoisomeraseI and has negligible effect on protein kinase C andtopoisomeraseII^[1]^[2].

IC₅₀& Target^[1]

Topoisomerase I

Traditional Cytotoxic Agents

体外研究
(In Vitro)

Rebeccamycin is an antitumor antibiotic produced by the actinomyceteSaccharotrix aerocolonigeneswith activity against several human tumor cell lines, including A549 (lung adenocarcinoma), HCT-116 (colon carcinoma), and KB (nasopharyngeal carcinoma)^[1].
Rebeccamycin shows antibacterial activity against several Gram-positive bacteria, includingStaphylococcus aureusandStreptococcus faecalis^[3].

体内研究
(In Vivo)

Rebeccamycin (2-256 mg/kg; i.p.; daily for 9 days) prolongs survival in B16 melanoma, L1210 leukemia^[2].

Animal Model:	CDF1 mice (B16 melanoma, L1210 leukemia)^[2]
Dosage:	2, 4, 8, 16, 32, 64, 128, 256 mg/kg
Administration:	I.p.; daily for 9 days
Result:	Prolongation of survival of the mice at dose levels ranging from 8 to 256 mg/kg.

分子量

570.38

Formula

C₂₇H₂₁Cl₂N₃O₇

CAS 号

93908-02-2

结构分类

Antibiotics
Other Antibiotics

来源

the mycelium

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.